Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts

Nearly all melanoma patients with a BRAF‐activating mutation will develop resistance after an initial clinical benefit from BRAF inhibition (BRAFi). The aim of this work is to evaluate whether metabolic imaging using hyperpolarized (HP) (13)C pyruvate can serve as a metabolic marker of early respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Acciardo, Stefania, Mignion, Lionel, Lacomblez, Estelle, Schoonjans, Céline, Joudiou, Nicolas, Gourgue, Florian, Bouzin, Caroline, Baurain, Jean‐François, Gallez, Bernard, Jordan, Bénédicte F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991684/
https://www.ncbi.nlm.nih.gov/pubmed/31833658
http://dx.doi.org/10.1111/jcmm.14890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991684/
https://www.ncbi.nlm.nih.gov/pubmed/31833658
http://dx.doi.org/10.1111/jcmm.14890

Ejemplares similares